Table 1

Identified unmet research needs of high priority within RA, PSA, AxSpa, SLE and other systemic autoimmune rheumatic diseases

Rheumatoid arthritisThe need to better define treatment ‘refractory’ states both phenotypically and molecularly
The need to focus on refractory patients in both the study of novel targeted therapies and in the study of existing therapies in novel combinations or sequences
Psoriatic arthritisUnderstanding differential therapeutic effects on different clinical domains in PsA such as enthesitis
Further evaluation of combination therapies and strategic trials including the use of sequential therapies, controlled withdrawal, the treatment of early disease and the treatment of monoarticular or oligoarticular disease
Ankylosing spondyloarthritisUnderstanding the role of the microbiome in disease pathogenesis and potential therapy
Understanding disease pathology specifically with regard to why Il-23 inhibition does not improve the disease.
Systemic lupus erythematosusImproving clinical trial design by reducing heterogeneity of participants, developing new outcome disease activity measures, standardising serological testing and conducting organ-specific trials
Consider alternative trial designs including adaptive trials and withdrawal trials
Other systemic autoimmune rheumatic diseasesImproving clinical trial design, specifically with reducing heterogeneity in disease endotypes and the use of organ-specific outcome measures
Identification of predictive biomarkers and the inclusion of patient-reported outcomes of specific manifestations (eg, calcinosis) for clinical trials
  • axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematous.